175 related articles for article (PubMed ID: 38687454)
1. Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3-4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study.
Rowan CG; Agiro A; Chan KA; Colman E; White K; Desai P; Dwyer JP
Adv Ther; 2024 Jun; 41(6):2381-2398. PubMed ID: 38687454
[TBL] [Abstract][Full Text] [Related]
2. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.
Obi Y; Thomas F; Dashputre AA; Goedecke P; Kovesdy CP
Kidney Med; 2024 Jan; 6(1):100757. PubMed ID: 38192434
[TBL] [Abstract][Full Text] [Related]
5. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
[TBL] [Abstract][Full Text] [Related]
6. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
[TBL] [Abstract][Full Text] [Related]
8. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
[TBL] [Abstract][Full Text] [Related]
9. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
[TBL] [Abstract][Full Text] [Related]
10. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
Morales J; Palmer BF
Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.
Georgianos PI; Liampas I; Kyriakou A; Vaios V; Raptis V; Savvidis N; Sioulis A; Liakopoulos V; Balaskas EV; Zebekakis PE
Int Urol Nephrol; 2017 Dec; 49(12):2217-2221. PubMed ID: 29027620
[TBL] [Abstract][Full Text] [Related]
12. Association of hyperkalemia with clinical outcomes in advanced chronic kidney disease.
Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
Nefrologia (Engl Ed); 2019; 39(5):513-522. PubMed ID: 31027897
[TBL] [Abstract][Full Text] [Related]
13. The frequency of hyperkalemia and its significance in chronic kidney disease.
Einhorn LM; Zhan M; Hsu VD; Walker LD; Moen MF; Seliger SL; Weir MR; Fink JC
Arch Intern Med; 2009 Jun; 169(12):1156-62. PubMed ID: 19546417
[TBL] [Abstract][Full Text] [Related]
14. Hyperkalemia in chronic heart failure with renal dysfunction or diabetes mellitus: Results from the TREAT HF study.
Murat S; Kaya H; Çavuşoğlu Y; Yılmaz MB
Turk Kardiyol Dern Ars; 2021 Apr; 49(3):198-205. PubMed ID: 33847269
[TBL] [Abstract][Full Text] [Related]
15. The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings.
Neuenschwander JF; Silverstein AR; Teigland CL; Kumar S; Zeng EY; Agiro AT; Pottorf WJ; Peacock WF
Adv Ther; 2023 Mar; 40(3):1204-1223. PubMed ID: 36652174
[TBL] [Abstract][Full Text] [Related]
16. Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4-5: Eight-Year Follow-up.
de Rooij ENM; de Fijter JW; Le Cessie S; Hoorn EJ; Jager KJ; Chesnaye NC; Evans M; Windahl K; Caskey FJ; Torino C; Szymczak M; Drechsler C; Wanner C; Dekker FW; Hoogeveen EK;
Am J Kidney Dis; 2023 Sep; 82(3):257-266.e1. PubMed ID: 37182596
[TBL] [Abstract][Full Text] [Related]
17. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study.
Adelborg K; Nicolaisen SK; Hasvold P; Palaka E; Pedersen L; Thomsen RW
PLoS One; 2019; 14(6):e0218739. PubMed ID: 31226134
[TBL] [Abstract][Full Text] [Related]
18. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
[TBL] [Abstract][Full Text] [Related]
19. Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy.
Chernin G; Gal-Oz A; Ben-Assa E; Schwartz IF; Weinstein T; Schwartz D; Silverberg DS
Clin Cardiol; 2012 Jan; 35(1):32-6. PubMed ID: 22057933
[TBL] [Abstract][Full Text] [Related]
20. Cost Consequence Analysis of the Management of Hyperkalemia by Patiromer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia.
Shaheen FAM; Meunier A; Altowaijri A; Faadhel TA; Al-Abdulkarim H; AlGabash A; Floros L
Saudi J Kidney Dis Transpl; 2022 Feb; 33(Supplement):S39-S52. PubMed ID: 37102523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
